133107-64-9
Chemical Structure
Insulin lispro
- CAS No.: 133107-64-9
- Formula:C257H383N65O77S6
- Molecular Weight:5807.63
SMILES: [Insulin lispro]
Biological Activity: Insulin lispro is a recombinant h-Insulin (HY-P0035) analog whose primary structure is identical to regular h-Insulin, except that the proline-lysine at positions B28 and B29 is translocated to lysine-proline, thereby reducing self-association. Insulin lispro stimulates insulin receptor internalization to early endosomes, induces receptor phosphorylation, intracellular internalization, and colocalization with the early endosome marker EEA1. Insulin lispro shows stronger inhibition of hepatic glucose production and stronger inhibition of glucagon secretion. Insulin lispro has lower mitogenic potency. Insulin lispro can be used in the study of diabetes[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Insulin lispro | Insulin lispro is a recombinant h-Insulin (HY-P0035) analog whose primary structure is identical to regular h-Insulin, except that the proline-lysine at positions B28 and B29 is translocated to lysine-proline, thereby reducing self-association. Insulin lispro stimulates insulin receptor internalization to early endosomes, induces receptor phosphorylation, intracellular internalization, and colocalization with the early endosome marker EEA1. Insulin lispro shows stronger inhibition of hepatic glucose production and stronger inhibition of glucagon secretion. Insulin lispro has lower mitogenic potency. Insulin lispro can be used in the study of diabetes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Moyers JS, et al. Internalization and localization of basal insulin peglispro in cells. Molecular and cellular endocrinology. 2017 Oct 15;454:23-38.
- [2]. Simpson D, et al. Insulin lispro: a review of its use in the management of diabetes mellitus. Drugs. 2007;67(3):407-34. [Content Brief]
- [3]. Pettis RJ, et al. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabetes technology & therapeutics. 2011 Apr;13(4):435-42.
